MMJ Group provided a snapshot of the companies currently listed under its portfolio.
Beleave Announces Joint Venture with Volero Brands
Beleave Inc and Volero Brands Inc are pleased to announce that they have entered into a definitive agreement to form a joint venture to develop, produce, and distribute cannabis extracts, topicals and edibles for the Canadian market.
"Our partnership with Volero will allow us to effectively produce the quality products clients and patients have come to expect from Beleave."
"We're excited to partner with Beleave and bring an entirely new product category to the Canadian market. Our team knows that the best results are delivered when great people come together to collaborate with a common vision. This is exactly the environment we have right now with the team at Beleave," said Sean Trustham, Volero CEO.
"This is just the beginning. As we continue to develop and introduce unique products in the coming months, we will keep setting ourselves and our brands apart to ensure that, in the end, we will have fully leveraged this opportunity to establish a leading position in the cannabis extracts markets."
"Innovation, strong leadership, and the ability to navigate the regulatory landscape are core capabilities required for differentiation and future success in the rapidly evolving Canadian cannabis market"Jeannette VanderMarel, Beleave CEO.
Canadians are increasingly looking for new and safe ways to consume cannabis, and this partnership allows Beleave to meet that need while maintaining strict protocols and introducing standardized products with higher margins.
Cannabis 2.0 regulations are in response to a significant and unmet demand in the legal medical cannabis market to provide more flexibility in how cannabis is consumed.
Leveraging Beleave's production capacity, scale, reach, and sales network to drive growth for new products in the Canadian market, the Partnership outlines plans for the roll-out of extracts, topicals and edibles throughout 2020, beginning with Flyte vape pens in December 2019.
Launching with six flavours, Flyte pens and refill cartridges are the first of a broader line of cannabinoid-based products Beleave and Volero intend to launch in the future.
Harvest One Begins Sales in Argentina
Harvest One, through its wholly owned licensed producer United Greeneries Ltd., has received permission from Health Canada to import Satipharm's CBD Gelpell® capsules into Canada for research and development purposes.
This achievement allows Harvest One to begin compliance testing and analysis for the Canadian market in anticipation of full-scale production in Canada in 2020.
Harvest One is also pleased to announce that Satipharm's CBD Gelpell® capsules are now available in Argentina for medical purposes, and our initial shipment has been received by the first patient.
In March 2017, the Argentine Congress approved a new medical cannabis law. This law authorises the import of cannabis products for sufferers of refractory epilepsy for patients with a doctor's prescription. Satipharm has signed an agreement with FederalMed to manage the importation and distribution of Satipharm's CBD Gelpell® capsules to patients.
"At Harvest One, we view the Satipharm CBD Gelpell® capsule as a key part of our health, wellness, and self-care strategy and are very excited to be taking the next step in bringing them to the Canadian market. With this import permit, Harvest One can continue the necessary preparations to bring this unique, effective product to Canada," said Grant Froese, Chief Executive Officer of Harvest One.
"We are equally excited to have our first shipment of Satipharm's CBD Gelpell® capsules to Argentina, which marks Harvest One's first entry into South America. This adds to our existing distribution which includes 2,000 stores in the UK and Ireland, on-line sales across the EU, and prescription sales in Australia."
Satipharm produces a CBD capsule using the propriety Gelpell® process. These capsules take a different approach to other cannabinoid pills currently on the market in Canada and internationally. Gelpell® capsules contain full spectrum hemp extract CBD in seamless gelatine beads.
These microbeads, contained in a hard gastro-resistant capsule, release the CBD in the small intestine and maximise the delivery of CBD to the body. Manufactured in Switzerland, and GMP certified, every Gelpell® capsule delivers a consistent dose of cannabinoids.
MediPharm Labs File Application to List Common Shares on the NASDAQ Stock Market
MediPharm Labs Corp a global leader in specialized, research-driven cannabis extraction, distillation and purification, is pleased to announce it has filed an application to list its common shares on the NASDAQ Stock Market.
The Company will continue to maintain the listing of its common shares on the Toronto Stock Exchange under the symbol "LABS".
"Listing alongside our peers on the NASDAQ will enhance our visibility and access to a larger base of institutional and retail shareholders in the U.S. and globally."
"We are thrilled to be entering the next phase of growth at MediPharm Labs including cross-listing on the NASDAQ, one of the world's foremost exchanges for emerging markets and technology, such as the burgeoning cannabis sector"Pat McCutcheon, Chief Executive Officer, MediPharm Labs.
In advance of its anticipated listing on the NASDAQ, MediPharm Labs will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission.
The listing of the Company's common shares on the NASDAQ remains subject to the approval of the NASDAQ and the satisfaction of all applicable listing and regulatory requirements, including the SEC declaring the Form 40-F Registration Statement effective.
If you'd like to access MMJ Group's full list of news updates click here
Disclaimer: past performance is not an indicator of future performance
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!